Table 2.
Expression of HSPs in hepatocarcinogenesis obtained by dot immunoblot analysis.
| HSP | Tumor/ non-tumor |
DN |
HCC |
P (r) | ||||
| LGDN (n = 11) | HGDN (n = 8) | E-HCC (n = 5) | GI (n = 12) | GII (n = 11) | GIII (n = 10) | |||
| HSP27 | < 0.5 | 1 | 1 | |||||
| 0.5-1.5 | 9 | 6 | 3 | 4 | 4 | 0.0021 | ||
| 1.5-2.5 | 2 | 1 | 2 | 6 | 2 | 2 | (0.407) | |
| > 2.5 | 2 | 3 | 5 | 4 | ||||
| HSP60 | < 0.5 | 1 | ||||||
| 0.5-1.5 | 10 | 6 | 4 | 4 | 5 | 4 | 0.0041 | |
| 1.5-2.5 | 1 | 2 | 1 | 4 | 6 | 4 | (0.372) | |
| > 2.5 | 3 | 2 | ||||||
| HSP70 | < 0.5 | |||||||
| 0.5-1.5 | 6 | 7 | 3 | 3 | 2 | 5 | 0.100 | |
| 1.5-2.5 | 5 | 2 | 4 | 8 | 4 | (0.220) | ||
| > 2.5 | 1 | 5 | 1 | 1 | ||||
| HSP90 | < 0.5 | 1 | ||||||
| 0.5-1.5 | 5 | 6 | 3 | 2 | 2 | 2 | 0.0071 | |
| 1.5-2.5 | 6 | 2 | 1 | 4 | 7 | 6 | (0.353) | |
| > 2.5 | 6 | 2 | 2 | |||||
| GRP78 < 0.5 | 1 | 1 | ||||||
| 0.5-1.5 | 5 | 3 | 3 | 2 | 3 | 2 | 0.0071 | |
| 1.5-2.5 | 5 | 4 | 1 | 4 | 3 | (0.355) | ||
| > 2.5 | 1 | 1 | 6 | 5 | 7 | |||
| GRP94 | < 0.5 | 1 | ||||||
| 0.5-1.5 | 7 | 1 | 2 | 1 | 5 | 4 | 0.571 | |
| 1.5-2.5 | 2 | 6 | 3 | 5 | 4 | 1 | (0.077) | |
| > 2.5 | 2 | 1 | 6 | 2 | 4 | |||
DN: dysplastic nodule; LGDN: low-grade DN; HGDN: high-grade DN; HCC: hepatocellular carcinoma; E: early; G: Edmondson-Steiner’s grade; n: number of cases; P: Spearman Correlation; (r): Correlation coefficient;
1
Value was statistically significant.